Headache: Experience with Large Multicenter Trials in the Treatment of Migraine Attacks

  • P. Tfelt-Hansen
  • K. Seidelin
Chapter

Abstract

In this chapter we will discuss experiences with randomised controlled trials (RCTs) in the acute treatment of migraine. With the introduction of the new 5-hydroxytryptamine (5HT)1B/1D receptor agonist sumatriptan [1], the first drug developed specifically for migraine, and recently other triptans, the focus in RCTs in migraine has overwhelmingly been on acute migraine treatment. Only one prophylactic drug, the antiepileptic drug sodium valproate, has been introduced in recent years [2–5]. This chapter is based partly on our personal experience with multicenter RCTs in acute migraine treatment (n = 6) in recent years, partly on what we have perceived as problems in published multicenter RCTs. More systematic reviews on RCTs in migraine therapy are available [5–17].

Keywords

Placebo Migraine Aspirin Caffeine Neurol 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Humphrey PPA, Feniuk W, Marriott AS, Tanner RJN, Jackson MR, Tucker ML. Preclinical studies on the anti-migraine drug, sumatriptan. Eur Neurol 1991; 31: 282–290.PubMedCrossRefGoogle Scholar
  2. 2.
    Jensen R, Brinck T, Olesen J. Sodium valproate has a prophylactic effect in migraine without aura: A triple-blind, placebo-controlled crossover study. Neurology 1994; 44: 647–651.Google Scholar
  3. 3.
    Mathew NT, Saper JR, Silberstein SD, Rankin L, Markley HG, Solomon S, et al. Migraine prophylaxis with divalproex. Arch Neurol 1995; 52: 281–286.PubMedCrossRefGoogle Scholar
  4. 4.
    Klapper J, On behalf of the Divalproex Sodium in Migraine Prophylaxis Study Group. Divalproex sodium in migraine prophylaxis: a dose-controlled study. Cephalalgia 1997; 17: 103–108.PubMedCrossRefGoogle Scholar
  5. 5.
    Steiner TJ, Tfelt-Hansen P. Antiepileptic drugs in migraine prophylaxis. In: Clesen J, Tfelt-Hansen P, Welch KMA, editors. The headaches. 2nd ed. Philadelphia: Zippincott Williams & Wilkins, 2000: 483–487.Google Scholar
  6. 6.
    Tfelt-Hansen P. Sumatriptan for the treatment of migraine attacks: a review of controlled clinical trials. Cephalalgia 1993; 13: 238–244.PubMedCrossRefGoogle Scholar
  7. 7.
    Plosker GL, McTavish D. Sumatriptan. A reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs 1994; 47: 622–651.PubMedCrossRefGoogle Scholar
  8. 8.
    Pilgrim AJ, Blakeborough P. The clinical efficacy of sumatriptan in the acute treatment of migraine. Rev Contemp Pharmacother 1994; 5: 295–309.Google Scholar
  9. 9.
    WiZkinson M, Pfaffenrath V, Schoenen J, et al. Migraine and cluster headache: their management with sumatriptan. A critical review of the current clinical experience. Cephalalgia 1995; 15: 337–357.Google Scholar
  10. 10.
    Perry CN, Markham A. Sumatriptan. An updated review of its use in migraine. Drugs 1998; 55: 889–922.PubMedCrossRefGoogle Scholar
  11. 11.
    Palmer KJ, Spencer CM. Zolmitriptan. CNS Drugs 1997; 7: 468–478.CrossRefGoogle Scholar
  12. 12.
    Rolan PE, Martin GR. Zolmitriptan: a new acute treatment for migraine. Exp Opin Invest Drugs 1998; 7: 633–652.CrossRefGoogle Scholar
  13. 13.
    Dahlöf C, Lines C. Rizatriptan: a new 5-HTIB/ID receptor agonist for the treatment of migraine. Exp Opin Invest Drugs 1999; 8: 671–686.CrossRefGoogle Scholar
  14. 14.
    Dooley M, Faulds D. Rizatriptan: a review of its efficacy in the management of migraine. Dugs 1999; 58: 699–723.Google Scholar
  15. 15.
    Gunasekara NS, Wiseman LR. Naratriptan. CNS Drugs 1997; 8: 402–408.CrossRefGoogle Scholar
  16. 16.
    Saxena PR, Tfelt-Hansen P. Triptans, 5-HTIBilD receptor agonists, in the acute treatment of migraine. In: Olesen J, TfeltHansen P, Welch KMA, editors. The headaches. 2nd ed. Philadelphia: Lippincott Williams & Wilkins, 2000: 411–438.Google Scholar
  17. 17.
    Tfelt-Hansen P, De Vries P, Saxena PR. Triptans in migraine: a comparative review of their pharmacology, pharmacokinetics and efficacy. Drugs, in press.Google Scholar
  18. 18.
    Tfelt-Hansen P, Henry P, Mulder K, Scheldewaert RG, Schoenen J, Chazot G. The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine. Lancet 1995; 346: 923–926.PubMedCrossRefGoogle Scholar
  19. 19.
    Oral Sumatriptan Dose-defining study Group. Sumatriptan: an oral dose-defining study. Eur Neurol 1991; 31: 300–305.CrossRefGoogle Scholar
  20. 20.
    Tfelt-Hansen P, McEwen J. Nonsteroidal antiinflammatory drugs in the acute treatment of migraine. In: Olesen J, TfeltHansen P, Welch KMA, editors. The headaches. 2nd ed. Philadelphia: Lippincott Williams & Wilkins, 2000: 391–397.Google Scholar
  21. 21.
    Russel MB, Holm-Thomsen 0E, Nielsen MR, Cleal A, Pilgrim AJ, Olesen J. A randomized, double-blind, placebo-controlled crossover study of subcutaneous sumatriptan in general practice. Cephalalgia 1994; 14: 291–296.CrossRefGoogle Scholar
  22. 22.
    Jensen K, Tfelt-Hansen P, Hansen EW, Krpis EH, Pedersen OS. Introduction of a novel self-injector for sumatriptan: a con-trolled clinical trial in general practice. Cephalalgia 1995; 15: 423–429.PubMedGoogle Scholar
  23. 23.
    Brennum J, Brinck T, Schriver L, Wanscher B, Soelberg Sorensen P, Tfelt-Hansen P, Olesen J. Sumatriptan has no clinically relevant effect in the treatment of episodic tension-type headache. Eur J Neurol 1996; 3: 23–28.CrossRefGoogle Scholar
  24. 24.
    International Headache Society Committee on Clinical Trials in Migraine. Guidelines for controlled trials of drugs in migraine. 1st ed. Cephalalgia 1991; 11: 1–12.Google Scholar
  25. 25.
    Multinational Oral sumatriptan and Cafergot Comparative Study Group. A randomized, double-blind comparison of sumatriptan in the acute treatment of migraine. Eur Neurol 1991; 31: 314–322.CrossRefGoogle Scholar
  26. 26.
    Oral Sumatriptan and Aspirin plus Metoclopramide Comparative Study group. A study to compare oral sumatriptan with oral aspirin plus oral metoclopramide in the treatment of migraine. Eur Neurol 1992; 32: 177–184.CrossRefGoogle Scholar
  27. 27.
    Myllylä VV, Havanka H, Herrala L, Kangasneimi P, Rautakorpi I, Turkka, Vapaatalo H, Eskerod O. Tolfenamic acid rapid release versus sumatriptan in the acute treatment of migraine: comparable effect in a double-blind, randomised, controlled, parallel-group study. Headache 1998; 38: 201–207.PubMedCrossRefGoogle Scholar
  28. 28.
    The Diclofenac-K/Sumatriptan Migraine Study Group. Acute treatment of migraine attacks: efficacy and safety of a nonsteroidal anti-inflammatory drug, diclofenac-potassium, in comparison to oral sumatriptan and placebo. Cephalalgia 1999; 19: 232–240.CrossRefGoogle Scholar
  29. 29.
    Winner P, Ricade O, Le Force B, Saper J, Margul B. A double-blind study of subcutaneous dihydroergotamine vs subcutaneous sumatriptan in the treatment of acute migraine. Arch Neurol 1996; 53: 180–184.PubMedCrossRefGoogle Scholar
  30. 30.
    Touchon J, Bertin L, Pilgrim AJ, Ashford E, Bes A. A comparison of subcutaneous sumatriptan and dihydroergotamine nasal spray in the acute treatment of migraine. Neurology 1996; 47: 361–365.PubMedCrossRefGoogle Scholar
  31. 31.
    (Monograph in Swedish on sumatriptan suppositories published on the Internet by the Swedish Medical Products Agency.)Google Scholar
  32. 32.
    Visser WH, Terwindt GM, Reines SA, Jiang K, Lines CR, Ferrari MD, for the Dutch/US Rizatriptan Study Group. Rizatriptan vs sumatriptan in the acute treatment of migraine. A placebo-controlled, dose-ranging study. Arch Neurol 1996; 53: 1132 1137.Google Scholar
  33. 33.
    Goadsby PJ, Ferrari MD, Clesen J, Stovner LJ, Senard JM, Jackson NC, Poole PH, for the Eletriptan Steering Committee. Electriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan. Neurology 2000; 54: 156–163.PubMedCrossRefGoogle Scholar
  34. 34.
    Reches A, On behalf of the Electriptan Steering Committee. Comparison of the efficacy, safety and tolerability of oral eletriptan and Cafergot for the acute treatment of migraine. Cephalalgia 1999; 19: 355.Google Scholar
  35. 35.
    Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988; 8 (Suppl 7): 1–96.Google Scholar
  36. 36.
    Rasmussen BK. Epidemiology of headache. Cephalalgia 1995; 15: 45–68.PubMedGoogle Scholar
  37. 37.
    Stewart WF, Lipton RB. Population-based clinical trials in headache. In: Olesen J, Tfelt-Hansen P, editors. Headache treatment: trial methodology and new drugs. New York: Lippincott-Raven, 1997: 65–70.Google Scholar
  38. 38.
    Pilgrim A. Methodology of clinical trials of sumatriptan in migraine and cluster headache. Eur Neurol 1991; 31: 295–299.PubMedCrossRefGoogle Scholar
  39. 39.
    Salonen R, Ashford EA, Hassani H and The S2EM11 Study Group. Patients preference for oral sumatriptan 25, 50 or 100 mg in the acute treatment of migraine: a double-blind, randomized, crossover study. Int J Clin Pract 1999; Suppl 105: 16–24.Google Scholar
  40. 40.
    Rederich G, Rapoport A, Cutler N, Hazelrigg R, Jamerson B. Oral sumatriptan for the long-term treatment of migraine: clinical findings. Neurology 1995; 45 (Suppl 7): S15 - S20PubMedGoogle Scholar
  41. 41.
    Kramer M, Matzura-Wolfe D, Polis A, et al. A placebo-controlled crossover study of rizatriptan in the treatment of multiple attacks. Neurology 1998; 51: 773PubMedCrossRefGoogle Scholar
  42. 42.
    Mathew NT, Asgharnejad M, Peykamian M, Laurenza A, on behalf on the Naratriptan S2Wa3003 Study Group. Naratrip tan is effective and well tolerated in the acute treatment of migraine: results of a double-blind, placebo-controlled crossover study. Neurology 1997; 49: 1485–1490.PubMedCrossRefGoogle Scholar
  43. 43.
    Rapoport AM, Ramadan NM, Adelman JU, Mathew NT, Elkind AH, Kudrow DB, et al., on behalf of the 017 Clinical Trial Study Group. Optimizing the dose of zolmitriptan (Zornig, 311C90) for the acute treatment of migraine: a multicenter, double-blind, placebo-controlled, dose range-finding study. Neurology 1997; 49: 1210–1218.PubMedCrossRefGoogle Scholar
  44. 44.
    Göbel H, Petersen-Braun M, Heinze A. Which properties do patients expect of new and improved drugs in the of primary headache disorders? In: Olesen J, Tfelt-Hansen P, editors. Headache treatment: trial methodology and new drugs. New York: Lippincott-Raven, 1997: 93–97.Google Scholar
  45. 45.
    Tfelt-Hansen P, Sperling B, Winter PDO’B. Transient addi tional effect of sumatriptan on ergotamine-induced constric tion of peripheral arteries in man. Clin Pharmacol Ther 1992; 51: 149.Google Scholar
  46. 46.
    Rapoport AM, Visser WH, Cutler NR, Alderton CJ, Paulsgrove LA, Davis RL, Ferrari MD. Oral sumatriptan in preventing headache recurrence after treatment of migraine attacks with subcutaneous sumatriptan. Neurology 1995; 45: 1505–1509PubMedCrossRefGoogle Scholar
  47. 47.
    Ferrari MD, James MH, Bates D, Pilgrim AJ, Ashford EA, Anderson BA, Nappi G. Oral sumatriptan: effect of a second dose, and treatment of headache recurrence. Cephalalgia 1994; 14: 330–338.PubMedCrossRefGoogle Scholar
  48. 48.
    Tfelt-Hansen P. How to define the best efficacy parameters for migraine. Cephalalgia 1997; 17 (Suppl 17): 6–9PubMedGoogle Scholar
  49. 49.
    Massiou H, Tzourio C, El Amrani M, Bousser MG. Verbal scales in the acute treatment of migraine: semantic categories and clinical relevance. Cephalalgia 1997; 17: 37–39.PubMedCrossRefGoogle Scholar
  50. 50.
    Tfelt-Hansen P, Schoenen J, Lauret D. Success rates of com bined oral lysine acetylsalicylate and metoclopramide, oral sumatriptan, and placebo depend on initial headache severity. In: Olesen J, Tfelt-Hansen P, editors. Headache treatment: trial methodology and new drugs. New York: Lippincott-Raven, 1997: 103–106Google Scholar
  51. 51.
    Tfelt-Hansen P. Complete relief (IHS criterion) or no or mild pain (Glaxo criterion)? Estimation of relative power in placebo-controlled clinical trials of sumatriptan. In: Olesen J, Tfelt-Hansen P, editors. Headache treatment: trial methodology and new drugs. New York: Lippincott-Raven, 1997: 157–160.Google Scholar
  52. 52.
    Cady RK, Dexter J, Sargent JD, Markley H, Osterhaus JT, Webster CJ. Efficacy of subcutaneous sumatriptan in repeated episodes of migraine. Neurology 1993;43:1363PubMedCrossRefGoogle Scholar
  53. 53.
    Tfelt-Hansen P. Efficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment: a systematic review based on number needed to treat. Cephalalgia 1998; 18: 532–538.PubMedCrossRefGoogle Scholar
  54. 54.
    Cady RK, Wendt JK, Kirchner JR, Sargent JD, Rothrock JF, Skaggs H. Treatment of acute migraine with subcutaneous sumatriptan. JAMA 1991; 265: 2831–2835.PubMedCrossRefGoogle Scholar
  55. 55.
    Subcutaneous Sumatriptan International Study Group. Treat ment of migraine attacks with sumatriptan. N Engl J Med 1991; 325: 316–321.Google Scholar

Copyright information

© Springer-Verlag London 2001

Authors and Affiliations

  • P. Tfelt-Hansen
  • K. Seidelin

There are no affiliations available

Personalised recommendations